Gate Neurosciences announced on February 18 that it acquired Boost Neuroscience for an undisclosed price. The seller was Catalio Capital Management, an investment management firm based in New York City.
Boost Neuroscience is a “stealth” biotechnology company focused on the discovery and development of novel synaptogenic targets and therapies. It was spun out of the Stanford University lab of Dr. Thomas Südhof, MD. The company, while owned by Catalio Capital Management, developed a proprietary platform that models neuronal network circuits using human iPSC cells to gain unparalleled insights into how molecules impact neuronal networks, synaptogenesis, synaptic function and neuroplasticity.
Gate Neurosciences is a synaptic health biotechnology company focused on advancing next-generation precision central nervous system (CNS) treatments that address growing needs in mental health. The company is developing a portfolio of novel mechanisms of action that enhance synaptic function to address neuropsychiatric and neurocognitive diseases, including major depressive disorder.
The acquisition will augment Gate Neurosciences’ existing translational research in synaptic function pharmacology, increase confidence in its internal clinical programs and expand Gate’s early-stage pipeline with novel target programs. Together, the companies’ complementary capabilities and pipelines create a pioneering force in the development of novel therapeutics that address synaptopathies or CNS diseases driven by synapse loss and dysfunction.
According to data in the LevinPro HC database, this transaction marks the 21st Biotechnology acquisition of 2025. Throughout 2024, there were 135 Biotechnology transactions reported.
